PGIM Jennison Health Sciences B
Name
As ofPrice
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
9.2%
1 yr return
6.7%
3 Yr Avg Return
-0.8%
5 Yr Avg Return
-7.0%
Net Assets
$1.9 B
Holdings in Top 10
35.1%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 2.22%
SALES FEES
Front Load N/A
Deferred Load 5.00%
TRADING FEES
Turnover 30.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$2,500
IRA
$1,000
Fund Classification
Fund Type
Open End Mutual Fund
Name
As ofPrice
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
PHLBX - Profile
Distributions
- YTD Total Return 9.2%
- 3 Yr Annualized Total Return -0.8%
- 5 Yr Annualized Total Return -7.0%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -1.57%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NamePGIM Jennison Health Sciences Fund
-
Fund Family NamePGIM Funds (Prudential)
-
Inception DateJun 30, 1999
-
Shares OutstandingN/A
-
Share ClassB
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerDavid Chan
Fund Description
PHLBX - Performance
Return Ranking - Trailing
Period | PHLBX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 9.2% | -12.0% | 23.1% | 29.23% |
1 Yr | 6.7% | 0.0% | 42.1% | 84.75% |
3 Yr | -0.8%* | -13.6% | 17.6% | 86.49% |
5 Yr | -7.0%* | -11.1% | 13.5% | 92.31% |
10 Yr | 6.5%* | -2.1% | 16.5% | 63.10% |
* Annualized
Return Ranking - Calendar
Period | PHLBX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 11.7% | 5.7% | 55.4% | 91.45% |
2022 | -19.0% | -25.3% | 21.5% | 91.89% |
2021 | 22.2% | -10.8% | 43.9% | 25.69% |
2020 | -19.1% | -31.6% | 6.9% | 65.09% |
2019 | -12.1% | -20.4% | 13.8% | 93.07% |
Total Return Ranking - Trailing
Period | PHLBX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 9.2% | -12.0% | 23.1% | 29.23% |
1 Yr | 6.7% | 0.0% | 42.1% | 84.75% |
3 Yr | -0.8%* | -13.6% | 20.6% | 92.79% |
5 Yr | -7.0%* | -11.1% | 18.3% | 95.19% |
10 Yr | 6.5%* | -2.1% | 18.7% | 80.95% |
* Annualized
Total Return Ranking - Calendar
Period | PHLBX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 11.7% | 5.7% | 55.4% | 91.45% |
2022 | -19.0% | -25.3% | 22.2% | 92.79% |
2021 | 22.2% | -10.8% | 45.8% | 34.86% |
2020 | -19.1% | -24.2% | 8.7% | 78.30% |
2019 | -12.1% | -16.6% | 15.2% | 95.05% |
PHLBX - Holdings
Concentration Analysis
PHLBX | Category Low | Category High | PHLBX % Rank | |
---|---|---|---|---|
Net Assets | 1.9 B | 2.42 M | 49.6 B | 23.88% |
Number of Holdings | 84 | 27 | 433 | 47.76% |
Net Assets in Top 10 | 658 M | 784 K | 18.8 B | 24.63% |
Weighting of Top 10 | 35.11% | 23.7% | 75.9% | 70.90% |
Top 10 Holdings
- Sarepta Therapeutics Inc 4.17%
- UnitedHealth Group Inc 4.02%
- Biomarin Pharmaceutical Inc 3.98%
- DexCom Inc 3.57%
- AstraZeneca PLC ADR 3.53%
- Vertex Pharmaceuticals Inc 3.47%
- Eli Lilly and Co 3.31%
- Humana Inc 3.29%
- Abbott Laboratories 2.91%
- Boston Scientific Corp 2.85%
Asset Allocation
Weighting | Return Low | Return High | PHLBX % Rank | |
---|---|---|---|---|
Stocks | 98.70% | 61.47% | 100.23% | 25.37% |
Cash | 1.20% | -0.23% | 32.46% | 72.39% |
Preferred Stocks | 0.11% | 0.00% | 6.63% | 9.70% |
Other | 0.00% | -3.74% | 6.07% | 53.73% |
Convertible Bonds | 0.00% | 0.00% | 0.00% | 36.57% |
Bonds | 0.00% | 0.00% | 0.06% | 43.28% |
Stock Sector Breakdown
Weighting | Return Low | Return High | PHLBX % Rank | |
---|---|---|---|---|
Healthcare | 99.67% | 73.33% | 100.00% | 53.73% |
Financial Services | 0.33% | 0.00% | 2.43% | 20.90% |
Utilities | 0.00% | 0.00% | 0.00% | 36.57% |
Technology | 0.00% | 0.00% | 20.28% | 44.78% |
Real Estate | 0.00% | 0.00% | 2.13% | 41.79% |
Industrials | 0.00% | 0.00% | 6.39% | 40.30% |
Energy | 0.00% | 0.00% | 0.00% | 37.31% |
Communication Services | 0.00% | 0.00% | 3.18% | 40.30% |
Consumer Defense | 0.00% | 0.00% | 1.05% | 42.54% |
Consumer Cyclical | 0.00% | 0.00% | 1.12% | 44.03% |
Basic Materials | 0.00% | 0.00% | 2.61% | 48.51% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | PHLBX % Rank | |
---|---|---|---|---|
US | 82.70% | 47.91% | 99.43% | 28.36% |
Non US | 16.00% | 0.00% | 43.93% | 57.46% |
PHLBX - Expenses
Operational Fees
PHLBX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 2.22% | 0.10% | 25.14% | 20.77% |
Management Fee | 0.72% | 0.00% | 1.25% | 51.49% |
12b-1 Fee | 1.00% | 0.00% | 1.00% | 82.19% |
Administrative Fee | N/A | 0.03% | 0.40% | N/A |
Sales Fees
PHLBX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | 5.00% | 1.00% | 5.00% | 13.64% |
Trading Fees
PHLBX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
PHLBX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 30.00% | 0.70% | 248.00% | 26.15% |
PHLBX - Distributions
Dividend Yield Analysis
PHLBX | Category Low | Category High | PHLBX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 0.05% | 38.81% |
Dividend Distribution Analysis
PHLBX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Annually | Annually | Annually | Annually |
Net Income Ratio Analysis
PHLBX | Category Low | Category High | PHLBX % Rank | |
---|---|---|---|---|
Net Income Ratio | -1.57% | -2.53% | 2.12% | 98.46% |
Capital Gain Distribution Analysis
PHLBX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
PHLBX - Fund Manager Analysis
Managers
David Chan
Start Date
Tenure
Tenure Rank
Jun 30, 1999
21.02
21.0%
David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.
Debra Netschert
Start Date
Tenure
Tenure Rank
Jan 28, 2015
5.42
5.4%
Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.01 | 22.98 | 8.6 | 20.35 |